Related Experiment Video
Updated: Aug 6, 2026
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
Pharmacologic and Non-Pharmacologic Interventions for Hypothalamic Obesity: An Updated Review
Anna Zenno1,2, Melinda Pierce3
1Department of Pediatrics, University of Washington School of Medicine, 4800 Sand Point Way NE, M/S OC.7.820, PO Box 5371, WA, Seattle, 98145, USA. annaz24@uw.edu.
Current Obesity Reports
|July 24, 2026
Summary
Hypothalamic obesity (HO) treatment is challenging, but new strategies like FDA-approved setmelanotide offer hope. Research is ongoing for more effective pharmacologic interventions for this refractory condition.
Area of Science:
- Endocrinology
- Neuroscience
- Obesity Medicine
Background:
- Hypothalamic obesity (HO) results from hypothalamic injury, disrupting energy balance, metabolism, and satiety.
- HO leads to refractory obesity resistant to conventional diet and exercise interventions.
- Effective long-term management of HO remains a significant clinical challenge.
Purpose of the Study:
- To summarize current treatment strategies for hypothalamic obesity (HO).
- To present the latest data on pharmacologic interventions for HO.
- To review new diagnostic criteria and emerging therapies for HO.
Main Methods:
- Review of current literature on hypothalamic obesity treatments.
- Summary of non-pharmacologic interventions (diet, physical activity).
- Analysis of pharmacologic options, including setmelanotide and drugs in development.
Main Results:
- New consensus diagnostic criteria for acquired HO have been established.
- Setmelanotide, targeting the melanocortin-4 receptor (MC4R) pathway, is FDA-approved.
- Metabolic and bariatric surgery are also discussed as treatment options.
- Emerging strategies address the complex pathophysiology of HO, though long-term data is limited.
Conclusions:
- Hypothalamic obesity management requires multifaceted approaches.
- Pharmacologic interventions, particularly MC4R agonists, show promise.
- Further research with controlled trials and long-term follow-up is crucial for optimizing HO treatment.
Related Concept Videos
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:24Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...